WO2009005124A1 - Double-stranded rna originating in lactic acid bacterium - Google Patents

Double-stranded rna originating in lactic acid bacterium Download PDF

Info

Publication number
WO2009005124A1
WO2009005124A1 PCT/JP2008/062066 JP2008062066W WO2009005124A1 WO 2009005124 A1 WO2009005124 A1 WO 2009005124A1 JP 2008062066 W JP2008062066 W JP 2008062066W WO 2009005124 A1 WO2009005124 A1 WO 2009005124A1
Authority
WO
WIPO (PCT)
Prior art keywords
double
lactic acid
stranded rna
acid bacterium
rna originating
Prior art date
Application number
PCT/JP2008/062066
Other languages
French (fr)
Japanese (ja)
Inventor
Ikuko Masuda
Daisuke Kaneko
Tadaomi Kawashima
Noriko Tsuji
Akemi Kosaka
Original Assignee
Kikkoman Corporation
National Institute Of Advanced Industrial Science And Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kikkoman Corporation, National Institute Of Advanced Industrial Science And Technology filed Critical Kikkoman Corporation
Priority to CN200880105541A priority Critical patent/CN101796187A/en
Priority to CA2694354A priority patent/CA2694354C/en
Priority to JP2009521668A priority patent/JP5099649B2/en
Priority to US12/452,405 priority patent/US8334371B2/en
Priority to EP08777818.9A priority patent/EP2169057B1/en
Publication of WO2009005124A1 publication Critical patent/WO2009005124A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

It is intended to provide an immunomodulator, which has a high safety and can be effectively incorporated into cells, and a method of producing the same. A double-stranded RNA originating in a lactic acid bacterium; an immunomodulator comprising the double-stranded RNA originating in a lactic acid bacterium as the active ingredient; and a method of producing the double-stranded RNA originating in a lactic acid bacterium. Lactic acid bacterial cells belonging to the genus Tetragenococcus, Pediococcus, Lactobacillus, Streptococcus, Leuconostoc, etc. can produce a double-stranded RNA having an immunomodulation effect therein.
PCT/JP2008/062066 2007-07-04 2008-07-03 Double-stranded rna originating in lactic acid bacterium WO2009005124A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN200880105541A CN101796187A (en) 2007-07-04 2008-07-03 Double-stranded RNA originating in lactic acid bacterium
CA2694354A CA2694354C (en) 2007-07-04 2008-07-03 Lactic acid bacteria-derived double-stranded rna
JP2009521668A JP5099649B2 (en) 2007-07-04 2008-07-03 Double-stranded RNA derived from lactic acid bacteria
US12/452,405 US8334371B2 (en) 2007-07-04 2008-07-03 Lactic acid bacteria-derived double-stranded RNA
EP08777818.9A EP2169057B1 (en) 2007-07-04 2008-07-03 Double-stranded rna originating in lactic acid bacterium

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007175694 2007-07-04
JP2007-175694 2007-07-04
JP2007-299243 2007-11-19
JP2007299243 2007-11-19

Publications (1)

Publication Number Publication Date
WO2009005124A1 true WO2009005124A1 (en) 2009-01-08

Family

ID=40226165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/062066 WO2009005124A1 (en) 2007-07-04 2008-07-03 Double-stranded rna originating in lactic acid bacterium

Country Status (6)

Country Link
US (1) US8334371B2 (en)
EP (1) EP2169057B1 (en)
JP (1) JP5099649B2 (en)
CN (1) CN101796187A (en)
CA (1) CA2694354C (en)
WO (1) WO2009005124A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027829A1 (en) * 2009-09-02 2011-03-10 京都府公立大学法人 Composition containing rna derived from lactic acid bacterium as active ingredient
WO2015004949A1 (en) 2013-07-12 2015-01-15 森永乳業株式会社 Novel lactobacillus and novel lactobacillus-containing medicine, food, beverage and feed
US9549956B2 (en) 2010-12-28 2017-01-24 Kirin Holdings Kabushiki Kaisha Agent for inducing interferon production containing lactic acid bacteria
WO2017110421A1 (en) * 2015-12-24 2017-06-29 キッコーマン株式会社 Method for producing macromolecular hyaluronic acid
WO2017175774A1 (en) * 2016-04-04 2017-10-12 キッコーマン株式会社 COMPOSITION FOR PROMOTING INTERFERON λ PRODUCTION AND METHOD FOR PRODUCING SAME
JP2018016580A (en) * 2016-07-27 2018-02-01 株式会社東洋発酵 Immunostimulatory composition
JP2018048087A (en) * 2016-09-21 2018-03-29 アダプトゲン製薬株式会社 Body weight or visceral fat increase inhibitor, or food composition for inhibiting increase of body weight or visceral fat, or feed composition for inhibiting increase of body weight or visceral fat
WO2018207924A1 (en) * 2017-05-12 2018-11-15 キッコーマン株式会社 Method for producing double-stranded rna-rich lactic acid bacterium, and said lactic acid bacterium
US11241463B2 (en) 2013-07-12 2022-02-08 Morinaga Milk Industry Co., Ltd. Lactic acid bacterium, drug, food or drink, and feed which contain the lactic acid bacterium

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742127B1 (en) * 2011-08-12 2019-10-09 Mello Biotechnology, Inc. Inducable expression from the eukaryotic pol-2 promoter in prokaryotes
CN102935238A (en) * 2012-07-27 2013-02-20 水爱生物科技（南通）有限公司 Application of yeast M-dsRNA as TLR3 agonist, and yeast M-dsRNA preparation method
US10196662B2 (en) * 2012-08-10 2019-02-05 Mello Biotechnology, Inc. Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors
CN105779442B (en) * 2016-05-19 2019-05-28 清华大学 A kind of native cellulose using the macro transcript profile RNA of flora extracting method
WO2018047979A1 (en) 2016-09-12 2018-03-15 イチビキ株式会社 Salt-tolerant lactobacillus, method of culturing salt-tolerant lactobacillus, and immunostimulant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006232790A (en) * 2005-02-28 2006-09-07 Meiji Milk Prod Co Ltd Immune response-reinforcing medicine and food composition each containing at oligonucleotide as active ingredient
JP2006325540A (en) * 2005-05-30 2006-12-07 Takanashi Milk Products Co Ltd Oligodeoxynucleotide and immunomodulating agent utilizing the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680575A (en) 1991-03-05 1994-03-22 Meiji Milk Prod Co Ltd Oral immunopotentiating agent
JP3174611B2 (en) 1992-02-28 2001-06-11 明治乳業株式会社 Immunostimulating composition
JP4112021B2 (en) 1994-02-16 2008-07-02 明治乳業株式会社 Immunostimulant using lactic acid bacteria
JPH0899887A (en) 1994-08-01 1996-04-16 Nichinichi Seiyaku Kk Immunopotentiator
JPH092959A (en) 1995-06-16 1997-01-07 Yakult Honsha Co Ltd Immuno-globulin e antibody production suppressant and antiallergic agent
JPH09124496A (en) 1995-10-31 1997-05-13 Nichinichi Seiyaku Kk Infection inihibitor
JPH09188627A (en) 1996-01-10 1997-07-22 Kyoto Pasutouule Kenkyusho Substance for improving interferon-producing ability and its production
JP3040711B2 (en) 1996-02-21 2000-05-15 ニチニチ製薬株式会社 Antitumor agent and method for producing the same
JP4064481B2 (en) 1996-10-11 2008-03-19 ハウスウェルネスフーズ株式会社 Immunostimulator
JPH10309178A (en) 1997-05-09 1998-11-24 Wakamoto Pharmaceut Co Ltd Antiallergic agent and fermented food containing bifidus bacterium as active component
JP2000095697A (en) 1998-09-18 2000-04-04 Advance Co Ltd Antiallergic agent
JP2003113114A (en) 2001-10-09 2003-04-18 Nichimo Co Ltd Immunostimulator
JP4308481B2 (en) 2002-06-18 2009-08-05 独立行政法人農業・食品産業技術総合研究機構 Antiallergic agent
JP4212838B2 (en) 2002-06-26 2009-01-21 カルピス株式会社 Antiallergic agent
JP4917025B2 (en) 2004-05-28 2012-04-18 サントリーホールディングス株式会社 A composition having an immunomodulatory action, comprising Lactobacillus pentosus
JP2006028047A (en) 2004-07-14 2006-02-02 Kikkoman Corp Interleukin 12 production promoter and method for producing the same
JP5312322B2 (en) * 2007-07-03 2013-10-09 キッコーマン株式会社 Interferon β production promoter and method for producing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006232790A (en) * 2005-02-28 2006-09-07 Meiji Milk Prod Co Ltd Immune response-reinforcing medicine and food composition each containing at oligonucleotide as active ingredient
JP2006325540A (en) * 2005-05-30 2006-12-07 Takanashi Milk Products Co Ltd Oligodeoxynucleotide and immunomodulating agent utilizing the same

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ICHIKAWA S. ET AL.: "MyD88 but Not TLR2, 4 or 9 Is Essential for IL-12 Induction by Lactic Acid Bacteria", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 71, no. 12, December 2007 (2007-12-01), pages 3026 - 3032, XP008128031 *
KITAZAWA H. ET AL.: "AT Oligonucleotides Inducing B Lymphocyte Activation Exist in Probiotic Lactobacillus gasseri", INT. J. FOOD MICROBIOL., vol. 65, no. 3, 2001, pages 149 - 162, XP003002302 *
KITAZAWA H. ET AL.: "IMmunostimulatory Oligonucleotide, CpG-like Motif Exists in Lactobacillus delbrueckii ssp. bulgaricus NIAI B6", INT. J. FOOD MICROBIOL., vol. 85, no. 1-2, 2003, pages 11 - 21, XP008128035 *
MASUDA S. ET AL.: "Immunomodulatory Effect of Halophilic Lactic Acid Bacterium Tetragenococcus halophilus Th221 from Soy Sauce Moromi Grown in High-salt Medium", INT. J. FOOD MICROBIOL., vol. 121, no. 3, February 2008 (2008-02-01), pages 245 - 252, XP022439569 *
NISHIMURA I.: "Tetragenococcus halophilus KK221 Kabu (Th221 Kabu) no Nihonsa RNA wa TLR3 o Kaishite Kogen Teiji Saibo Karano IL-12 Sansei o Yudo suru", JOURNAL OF JAPAN SOCIETY FOR LACTIC ACID BACTERIA, vol. 19, no. 2, June 2008 (2008-06-01), pages 117 *
TAKAHASHI N. ET AL.: "An Immunostimulatory DNA Sequence from a Probiotic Strain of Bifidobacterium longum Inhibits IgE Production in vitro", FEMS IMMUNOL. MED. MICROBIOL., vol. 46, no. 3, 2006, pages 461 - 469, XP009069320 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5690270B2 (en) * 2009-09-02 2015-03-25 京都府公立大学法人 A composition comprising RNA derived from lactic acid bacteria as an active ingredient
JPWO2011027829A1 (en) * 2009-09-02 2013-02-04 京都府公立大学法人 A composition comprising RNA derived from lactic acid bacteria as an active ingredient
US8765706B2 (en) 2009-09-02 2014-07-01 Kyoto Prefectural Public University Corporation Composition comprising rna derived from lactic acid bacterium as effective component
WO2011027829A1 (en) * 2009-09-02 2011-03-10 京都府公立大学法人 Composition containing rna derived from lactic acid bacterium as active ingredient
US11944657B2 (en) 2010-12-28 2024-04-02 Kirin Holdings Kabushiki Kaisha Agent for inducing interferon production containing lactic acid bacteria
US9549956B2 (en) 2010-12-28 2017-01-24 Kirin Holdings Kabushiki Kaisha Agent for inducing interferon production containing lactic acid bacteria
US11224623B2 (en) 2010-12-28 2022-01-18 Kirin Holdings Kabushiki Kaisha Agent for inducing interferon production containing lactic acid bacteria
US10220060B2 (en) 2010-12-28 2019-03-05 Kirin Holdings Kabushiki Kaisha Agent for inducing interferon production containing lactic acid bacteria
US10064903B2 (en) 2013-07-12 2018-09-04 Morinaga Milk Industry Co., Ltd. Lactic acid bacterium, drug, food or drink, and feed which contain the lactic acid bacterium
WO2015004949A1 (en) 2013-07-12 2015-01-15 森永乳業株式会社 Novel lactobacillus and novel lactobacillus-containing medicine, food, beverage and feed
US11241463B2 (en) 2013-07-12 2022-02-08 Morinaga Milk Industry Co., Ltd. Lactic acid bacterium, drug, food or drink, and feed which contain the lactic acid bacterium
US10653730B2 (en) 2013-07-12 2020-05-19 Morinaga Milk Industry Co., Ltd. Lactic acid bacterium, drug, food or drink, and feed which contain the lactic acid bacterium
JP2017112901A (en) * 2015-12-24 2017-06-29 キッコーマン株式会社 Method for producing high-molecular-weight hyaluronic acid
WO2017110421A1 (en) * 2015-12-24 2017-06-29 キッコーマン株式会社 Method for producing macromolecular hyaluronic acid
WO2017175774A1 (en) * 2016-04-04 2017-10-12 キッコーマン株式会社 COMPOSITION FOR PROMOTING INTERFERON λ PRODUCTION AND METHOD FOR PRODUCING SAME
JPWO2017175774A1 (en) * 2016-04-04 2019-02-21 キッコーマン株式会社 Composition for promoting production of interferon λ and method for producing the same
JP2018016580A (en) * 2016-07-27 2018-02-01 株式会社東洋発酵 Immunostimulatory composition
JP7165363B2 (en) 2016-07-27 2022-11-04 株式会社東洋発酵 Immunostimulatory composition
JP2021107446A (en) * 2016-07-27 2021-07-29 株式会社東洋発酵 Immunostimulatory composition
JP2018048087A (en) * 2016-09-21 2018-03-29 アダプトゲン製薬株式会社 Body weight or visceral fat increase inhibitor, or food composition for inhibiting increase of body weight or visceral fat, or feed composition for inhibiting increase of body weight or visceral fat
JP6480090B1 (en) * 2017-05-12 2019-03-06 キッコーマン株式会社 Method for producing lactic acid bacteria having high double-stranded RNA content and the lactic acid bacteria
US11518976B2 (en) 2017-05-12 2022-12-06 Kikkoman Corporation Method for producing double-stranded RNA-rich lactic acid bacterium, and said lactic acid bacterium
WO2018207924A1 (en) * 2017-05-12 2018-11-15 キッコーマン株式会社 Method for producing double-stranded rna-rich lactic acid bacterium, and said lactic acid bacterium

Also Published As

Publication number Publication date
EP2169057A4 (en) 2010-07-28
CA2694354C (en) 2018-01-16
JPWO2009005124A1 (en) 2010-08-26
EP2169057A1 (en) 2010-03-31
EP2169057B1 (en) 2015-09-30
US8334371B2 (en) 2012-12-18
JP5099649B2 (en) 2012-12-19
CN101796187A (en) 2010-08-04
CA2694354A1 (en) 2009-01-08
US20110159552A1 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
WO2009005124A1 (en) Double-stranded rna originating in lactic acid bacterium
EP1859022A4 (en) Novel acid tolerant lactobacillus sakei probio- 65 with the ability of growth suppression of pathogenic microorganisms and the anti-allergic effect
WO2014018596A3 (en) Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides
EP1812023B8 (en) Lactic acid bacteria as probiotic strains and compositions containing same
NZ596788A (en) Use of selected lactic acid bacteria for reducing infantile colic
WO2008129841A1 (en) Composition comprising lactic acid bacterium having high anti-allergic activity, and method for production of the lactic acid bacterium
EP1634600A4 (en) Antiallergic composition
EP2062968A4 (en) Bacterial strain having anti-allergic activity, and beverage, food and anti-allergic agent comprising cell of the bacterial strain
WO2009095436A3 (en) Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof
WO2010064930A8 (en) Use of lactic acid bacteria to treat or prevent eczema
MX2012003916A (en) Bacterial strains and variants thereof that can degrade polylactic acid, and uses of same.
WO2008073841A3 (en) Lactobacillus buchneri strain ln1297 and its use to improve aerobic stability of silage
WO2009066537A1 (en) Immunoregulatory function inducer and food composition
CA2710820A1 (en) Method for producing fermented milk
NZ601532A (en) Method for constructing novel bacterium belonging to the genus bifidobacterium
WO2008073853A8 (en) Lactobacillus buchneri strain ln5689 and its use to improve aerobic stability of silage
WO2007015132A3 (en) Use of specific lactic bacteria for the preparation of immunomodulating compositions
WO2010101855A3 (en) Microbial derived isoprene and methods for making the same
WO2009008656A3 (en) A soap composition for atopic dermatitis containing fermented extract of xanthium strumarium l. and preparation method thereof
WO2008073839A3 (en) Lactobacillus buchneri strain ln1286 and its use to improve aerobic stability of silage
WO2009005123A1 (en) INTERFERON-β PRODUCTION PROMOTER, AND METHOD FOR PRODUCTION THEREOF
WO2012016177A3 (en) Genetically modified microbes producing increased levels of acetyl-coa derived compounds
EP1817408A4 (en) Bacterial packaging strains usefuel for generation and production of recombinant double-stranded rna nucleocapsids and uses thereof
WO2011048554A3 (en) Combination of a probiotic lysate and a c-glycoside derivative
WO2012040224A3 (en) Oral composition and method of forming and using same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880105541.3

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2009521668

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777818

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2694354

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008777818

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12452405

Country of ref document: US